DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/d2kh2b/global_rheumatoid) has announced the addition of the "Global Rheumatoid Arthritis Epidemiology and Patient Flow Analysis - 2012" report to their offering.
Fore Pharma announced the results of its Rheumatoid Arthritis patient population study in a new report Global Rheumatoid Arthritis Epidemiology and Patient Flow Analysis - 2012'. The report provides insights into Rheumatoid Arthritis epidemiology, Rheumatoid Arthritis diagnosed patients, and Rheumatoid Arthritis treatment rate for top seven pharmaceutical markets. The study measures key indicators such as prevalence of Rheumatoid Arthritis derived from epidemiological analysis, percentage of patients diagnosed with Rheumatoid Arthritis, and percentage of patients treated with Rheumatoid Arthritis therapy.
The study helps executives estimate Rheumatoid Arthritis market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.
The report provides estimates and forecasts of Rheumatoid Arthritis prevalence, Rheumatoid Arthritis diagnosis rate, and Rheumatoid Arthritis treatment rate for the period 2012-2019. The information is presented by leading geographies including the US, Germany, France, Spain, Italy, UK, and Japan. The study design is based on collection and interpretation of data from registries, scientific journals and literatures, government databases and other secondary sources.
For more information visit http://www.researchandmarkets.com/research/d2kh2b/global_rheumatoid
Source: Research and Markets